Insider Selling: Sera Prognostics (NASDAQ:SERA) CEO Sells $14,044.00 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 7,022 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $2.00, for a total transaction of $14,044.00. Following the completion of the sale, the chief executive officer owned 837,848 shares of the company’s stock, valued at $1,675,696. This trade represents a 0.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenya Lindgardt also recently made the following trade(s):

• On Tuesday, September 8th, Zhenya Lindgardt sold 20,139 shares of Sera Prognostics stock. The stock was sold at an average price of $2.00, for a total value of $40,278.00.

Sera Prognostics Stock Performance

SERA opened at $2.03 on Monday. The business’s fifty day moving average is $2.05 and its two-hundred day moving average is $2.01. The company has a market cap of $80.08 million, a price-to-earnings ratio of -3.03 and a beta of 0.98. Sera Prognostics, Inc. has a one year low of $1.56 and a one year high of $3.95.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. On average, analysts predict that Sera Prognostics, Inc. will post -0.62 EPS for the current fiscal year.

Institutional Trading of Sera Prognostics

Several hedge funds and other institutional investors have recently bought and sold shares of SERA. Squarepoint Ops LLC grew its holdings in shares of Sera Prognostics by 8.9% during the 3rd quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock worth $285,000 after purchasing an additional 7,643 shares during the period. Arkadios Wealth Advisors purchased a new position in Sera Prognostics in the first quarter valued at approximately $25,000. Citadel Advisors LLC lifted its position in Sera Prognostics by 1.9% during the third quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock valued at $2,000,000 after buying an additional 12,439 shares in the last quarter. Lido Advisors LLC acquired a new position in Sera Prognostics during the third quarter valued at approximately $68,000. Finally, Cetera Investment Advisers purchased a new stake in Sera Prognostics during the fourth quarter worth approximately $74,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SERA has been the subject of a number of research reports. Weiss Ratings upgraded shares of Sera Prognostics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Craig Hallum assumed coverage on shares of Sera Prognostics in a research report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.50.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.